CNAT - Conatus Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
11.94M
Enterprise Value 3
-16.27M
Trailing P/E
N/A
Forward P/E 1
-1.44
PEG Ratio (5 yr expected) 1
-0.02
Price/Sales (ttm)
0.36
Price/Book (mrq)
0.50
Enterprise Value/Revenue 3
-0.50
Enterprise Value/EBITDA 6
1.13

Trading Information

Stock Price History

Beta (3Y Monthly) 2.25
52-Week Change 3-92.71%
S&P500 52-Week Change 38.19%
52 Week High 35.8900
52 Week Low 30.2500
50-Day Moving Average 30.3406
200-Day Moving Average 30.5739

Share Statistics

Avg Vol (3 month) 3711.35k
Avg Vol (10 day) 3618.57k
Shares Outstanding 533.17M
Float 32.33M
% Held by Insiders 13.34%
% Held by Institutions 124.84%
Shares Short (Sep 30, 2019) 41.27M
Short Ratio (Sep 30, 2019) 41.18
Short % of Float (Sep 30, 2019) 44.04%
Short % of Shares Outstanding (Sep 30, 2019) 43.82%
Shares Short (prior month Aug 30, 2019) 41.82M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -42.26%
Operating Margin (ttm)-43.91%

Management Effectiveness

Return on Assets (ttm)-17.51%
Return on Equity (ttm)-63.06%

Income Statement

Revenue (ttm)32.89M
Revenue Per Share (ttm)1.03
Quarterly Revenue Growth (yoy)23.00%
Gross Profit (ttm)-7.78M
EBITDA -14.36M
Net Income Avi to Common (ttm)-13.9M
Diluted EPS (ttm)-0.4350
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)28.75M
Total Cash Per Share (mrq)0.87
Total Debt (mrq)535k
Total Debt/Equity (mrq)2.22
Current Ratio (mrq)2.96
Book Value Per Share (mrq)0.73

Cash Flow Statement

Operating Cash Flow (ttm)-29.53M
Levered Free Cash Flow (ttm)-20.95M